Plant Transgene Expression Modulation With Tissue-Specific RNAi
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies struggle to achieve precise and tissue-specific regulation of transgene expression in plants, leading to unwanted expression in non-target tissues and developmental stages.
Innovation Solution
Utilizing endogenous small RNA molecules, such as miRNAs and siRNAs, to target specific tissues and regulate transgene expression through the plant's native RNA interference machinery, incorporating these molecules into expression cassettes to achieve tissue-specific downregulation of transgenes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional promoter-based regulation is used to control transgene expression, then expression can be maintained in all tissues, but precise tissue-specific regulation cannot be achieved leading to unwanted expression in non-target tissues
Solution Approach 1:
The patent applies local quality by making the transgene expression properties different in different tissues. Specifically, the transgene is engineered to contain a target site for a tissue-specific miRNA, so that the transgene is suppressed only in tissues where that miRNA is naturally expressed. This creates local suppression in specific tissues (e.g., roots, seeds, pollen) while maintaining expression in other tissues, achieving precise spatial control of transgene expression without affecting the entire plant.
2Object-generated harmful factors
If transgene expression is suppressed in specific tissues using RNAi, then unwanted expression is reduced, but the complexity of the expression system increases
Solution Approach 1:
The patent employs self-service by utilizing the plant's own endogenous miRNA molecules and native RNAi machinery to suppress the transgene. Instead of introducing external suppression systems or complex regulatory elements, the invention leverages naturally occurring plant components (endogenous miRNAs that are already present and tissue-specific in the plant) to achieve the suppression. The transgene is simply engineered to contain a target site complementary to the endogenous miRNA, allowing the plant's own biological systems to perform the suppression function.
3Productivity
If constitutive promoters are used for transgene expression, then high expression levels are maintained, but tissue-specific downregulation cannot be achieved
Solution Approach 1:
The patent applies segmentation by dividing the transgene expression control into two functional components: (1) a constitutive promoter that drives high-level expression across all tissues, and (2) a tissue-specific suppression mechanism using endogenous miRNA target sites. This segmentation allows the constitutive promoter to maintain high productivity throughout the plant, while the miRNA target sites provide tissue-specific downregulation in selected tissues. The two components work together to achieve both high overall expression and precise spatial control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables selective and efficient suppression of transgene expression in desired tissues, maintaining high expression in other tissues, overcoming limitations of conventional promoter-based regulation.
Implementation Method 1
RNA interference (RNAi) is a process utilizing endogenous cellular pathways, whereby an interfering RNA (iRNA) molecule (e.g., a dsRNA molecule) that is specific for a target gene sequence results in the reduced expression (e.g., by degradation) of the mRNA encoded thereby.
Implementation Method 2
Post-transcriptional gene silencing (translational repression) occurs when the guide strand binds specifically to a complementary sequence of an mRNA molecule and induces cleavage by Argonaute, the catalytic component of the RISC complex.
Data Source
AI summary
This disclosure concerns the use of endogenous plant RNAi machinery to preferentially or specifically reduce transgene expression. In some embodiments, the disclosure concerns specific reduction of transgene expression in seed tissues of a dicot plant.